New shot aims to reverse liver scarring in MASH patients
NCT ID NCT07620366
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests a new drug called QL2401 in 132 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate liver scarring. Participants receive weekly injections of either QL2401 or a placebo for 48 weeks. The main goal is to see if the drug reduces liver fat measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- QL2401 (a recombinant fusion protein given as a weekly injection)
- What this could lead to
- If successful, this could point toward a new treatment to reduce liver fat and fibrosis in people with MASH, potentially slowing or stopping liver damage.
- What could go wrong
- This is an early Phase 2 trial with only 132 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Weight-Loss surgery beat drugs for advanced liver damage?
- Can a single gene therapy injection reverse fatty liver disease?
- Navy beans take on fatty liver: a diet swap put to the test
- Could a tailored diet make a MASH drug work better?
- New injections aim to melt liver fat in MASH patients
- New drug aims to melt liver fat and stop scarring in MASH patients